Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Scleroderma and Related Disorders|April 6, 2022
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung diseaseLutz Wollin, Jörg Hw Distler, Christopher P Denton, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 9, 2025
Population Pharmacokinetics and Exposure-Response Model-Based Bayesian Extrapolation of FVC-Based Efficacy Endpoints From Adults to Pediatric Patients Receiving NintedanibSonja Hartmann, Anna Chan Kwong, Jakob Ribbing, et al.
Respiratory Research|July 17, 2015
Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthmaKai-Michael Beeh, Craig LaForce, Martina Gahlemann, et al.
Scientific Reports|May 24, 2022
An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP)Ilaria Campo, Federica Meloni, Martina Gahlemann, et al.
European Journal of Drug Metabolism and Pharmacokinetics|October 19, 2021
A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung DiseaseMadelon C Vonk, Alfredo Guillén-Del-Castillo, Michael Kreuter, et al.
Rheumatology (Oxford, England)|November 6, 2020
Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort studyQiang Li, Laura Wallace, Padmaja Patnaik, et al.
Respiratory Research|August 19, 2015
Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover studyPaul M O'Byrne, Tony D'Urzo, Ekkehard Beck, et al.
Modern Rheumatology|April 4, 2020
Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trialMasataka Kuwana, Takashi Ogura, Shigeki Makino, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2011
Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trialHuib A M Kerstjens, Bernd Disse, Winfried Schröder-Babo, et al.
Annals of the Rheumatic Diseases|August 16, 2022
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ONYannick Allanore, Madelon C Vonk, Oliver Distler, et al.
Pageof 2